Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Glimepiride, Empagliflozin and Sitagliptin With Metformin in Type 2 Diabetes Mellitus
NCT06759922Phase 4Completed
- Sponsor
- Bahria University
- Start
- Jan 2025
- Primary completion
- Mar 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of liquid metformin (Aspargo Labs), glimepiride, empagliflozin and sitagliptin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Bahria University. Primary endpoints: Glycated Hemoglobin at 12 weeks, Fasting Blood Sugar at 12 weeks and 1 more. Started Jan 2025; status: completed.
02
Drugs
liquid metformin (Aspargo Labs)glimepirideempagliflozinsitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06759922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06759922.